CFDE Data Portal | Search RAMACL

	Label	Description
	RAMACL Gene (Entity type)	ENSG00000235272 - RNA guanine-7 methyltransferase activating subunit like
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 1 V 6 FULVESTRANT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE224105 GSE224108 zearalenone 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE190178 MEK CDK8 inhibition 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE110580 1 V 0 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 0 V 1 PARTHENOLIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 10 V 6 FULVESTRANT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

RAMACL

ENSG00000235272 - RNA guanine-7 methyltransferase activating subunit like

GSE228017 parthenolide 0 v 1 human up

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human up

A Gene Set from LINCS

GSE216540 1 V 6 FULVESTRANT HUMAN UP

A Gene Set from LINCS

GSE224105 GSE224108 zearalenone 3 v 2 human up

A Gene Set from LINCS

GSE190178 MEK CDK8 inhibition 1 v 4 human up

A Gene Set from LINCS

GSE110580 1 V 0 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE228017 0 V 1 PARTHENOLIDE HUMAN UP

A Gene Set from LINCS

GSE216540 10 V 6 FULVESTRANT HUMAN UP

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.